Evidence map›Paper›PMID 39106432›Full record

ArticleBlood advances2024

Inhibition of MICA and MICB shedding enhances memory-like NK-cell-mediated cytotoxicity against multiple myeloma.

Sabrin Tahri, Sara Piccinelli, Nang Kham Su, Luisa Lampe, Han Dong, Juliana Vergara Cadavid, Rebecca Boiarsky, Natalie Papazian, Elizabeth D Lightbody, Amanda Cao and 13 more

Abstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Identification of novel molecular subtypes in ovarian cancerThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sabrin TahriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-8616-6607
Sara PiccinelliDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Nang Kham SuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0003-2875-6590
Luisa LampeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Han DongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Juliana Vergara CadavidDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-1137-8098
Rebecca BoiarskyCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.ORCID 0000-0002-8817-8086
Natalie PapazianDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Elizabeth D LightbodyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Amanda CaoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jean-Baptiste AlbergeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-4218-7294
Lucas Ferrari de AndradePrecision Immunology Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai Hospital, New York, NY.ORCID 0000-0002-2137-2271
Mahshid RahmatDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Yujia ShenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Laura Blanco FernándezClínica Universidad de Navarra, Center for Applied Medical Research, CIBERONC, IDISNA, Pamplona, Spain.ORCID 0000-0002-1859-0884
Aintzane ZabaletaClínica Universidad de Navarra, Center for Applied Medical Research, CIBERONC, IDISNA, Pamplona, Spain.
Andreas GüntherMedical Department, Christian-Albrechts University, Kiel, Germany.
Gad GetzCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.
Pieter SonneveldDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-0808-2237
Tom CupedoDepartment of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Kai W WucherpfennigDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.ORCID 0000-0002-1829-302X
Irene M GhobrialDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-7361-3092
Rizwan RomeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Funding

THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4M
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D PathwayR01CA238039 · NCI · DANA-FARBER CANCER INST · PI Kai W Wucherpfennig · 2019 to 2026
$4.2M
NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA238039
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Histocompatibility Antigens Class IKiller Cells, NaturalMultiple MyelomaCell Line, TumorCytotoxicity, ImmunologicHumansImmunologic MemoryHistocompatibility Antigens Class IMHC class I-related chain AMICB antigen

Identifiers

PMID39106432
PMCPMC11568787

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.